Use of incretin-based therapies in women using hormone replacement therapy (HRT)
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
Semaglutide and tirzepatide result in delayed gastric emptying and gastrointestinal side effects are common. The impact of these medications on efficacy of co-prescribed oral hormone medications within HRT are unknown. The effect on absorption and bioavailability of combination oral contraceptive (COC) varies by incretin-based products. Reduced bioavailability is seen with tirzepatide 22 . Semaglutide may confer similar effects through its effects on gastric emptying, but small studies show no adverse effects on COC absorption 23,24 . Eli Lilly has provided data showing that administration of a COC (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate) in the presence of a single dose of tirzepatide (5 mg) resulted in a reduction of oral contraceptive Cmax (maximum drug concentration) by 55 to 66%, with a 16 to 23% reduction in AUC (Area Under the Curve) and a delay in Tmax (time to achieve Cmax) of 2.5 to 4.5 hours. These effects may be due to the impact of tirzepatide on gastric emptying. The company therefore advises patients using a COC to switch to a non-oral contraceptive method, or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with tirzepatide 25 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146 · cited 1×
“Use of incretin-based therapies in women using hormone replacement therapy (HRT) The prevalence of T2D is also increasing 10,11 .”
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Crosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,333
The obesity transition: stages of the global epidemic
Jaacks, L. M., Vandevijvere, S., Pan, A., McGowan, C. J., Wallace, C., Imamura, F., Mozaffarian, D., Swinburn, B., & Ezzati, M. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30026-9 · Cited by 1,193
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462 · cited 1×
“These medications result in significantly greater weight loss compared with placebo 12,13 and improvement in HbA1c in patient with diabetes 14 .”
Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., Sattar, N., Sun, M. C., Wittert, G., Pinto, F. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac187 · Cited by 362
Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., Lingvay, I., Colhoun, H. M., Plutzky, J., Kosiborod, M. N., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01498-3 · Cited by 275
Research works printed but not linked: 2
- Kapkayeva S, Ginzburg R. Possible drug interaction between GLP-1 agonist and oral contraceptives. Reproductive health access project, 2025. https://www.reproductiveaccess.org/resource/possible-drug-interaction-between-glp-1-agonist-and-oral-contraceptives/.
- Zentiva UK. Progesterone 100 mg Capsules, soft [summary of product characteristics]. Zentiva. 2024. https://www.medicines.org.uk/emc/product/15401/smpc#gref.
Cited by
Understanding pharmacokinetic variability in women across different life stages
Campesi, I., Capobianco, G., Virdis, G., & Franconi, F. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2608753 · Cited by 1
“Therefore, it advisable in incretin-treated patients to switch to transdermal-estrogen-based HRT [10].”
Balan, V. E., Yureneva, S. V., Yarmolinskaya, M. I., Andreeva, E. N., Drapkina, O. M., Baranov, I. I., Hirschberg, A. L., Cano, A., Berns, S. A., Yavelov, I. S., et al. (2026) · Bulletin of Reproductive Health · doi:10.14341/brh12804
Viana, D. P. D. C., Invitti, A. L., Jacobsen, L., & Schor, E. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109116
Metadata
- Authors
- Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A.
- Affiliations
- Spire Manchester Hospital (GB)
- Department of Gynaecological Oncology, Imperial College London, London, UK
- University of Manchester (GB)
- Corresponding author
- Mukherjee, Annice
- Venue
- Post Reproductive Health
- Publisher
- Informa UK Limited
- Published
- 2025-05-16
- Volume
- 31
- Issue
- 2
- Pages
- 127-131
- ISSN
- 2053-3370 (ISSN-L)
- 2053-3691
- 2053-3705
- OpenAlex
- W4410426997
- Cited by
- 3
- References
- 24
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Post Reproductive Health (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- Astellas, Novartis, Lilly
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- incretin-based therapy, hormone replacement therapy, women, type 2 diabetes, postmenopausal women, drug interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of incretin-based therapies in women using hormone replacement therapy (HRT). https://app.cochat.ai/papers/10.1177/20533691251343069
- The paper
- Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A. (2025). Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reproductive Health. https://doi.org/10.1177/20533691251343069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.